This phase 3 study will evaluate the immunogenicity and safety of 9-valent HPV recombinant
vaccine in Chinese females aged 9 to 45 years
This study (protocol 9-HPV-3003) is an immunogenicity and safety study in the subjects (9-19
years of age) who received the 9-valent HPV recombinant vaccine compared with the subjects
(20-45 years of age). In this study, we will assess whether the immunogenicity of the
9-valent HPV vaccine given 3-dose schedule in the subjects (9-19 years of age) in noninferior
to that in the subjects (20-45 years of age) receiving 3 doses, while assessing the safety of
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.